The main manifestations of nephrotic syndrome include proteinuria, hypoalbuminemia, edema, hyperlipidemia and lipiduria. Common causes of nephrotic syndrome are diabetic nephropathy, minimal change disease (MCD), focal and segmental glomerulosclerosis (FSGS) and membranous nephropathy. Among the primary glomerular diseases, MCD is usually sensitive to glucocorticoid treatment, whereas the other diseases show variable responses 1 . Despite the identification of key structural proteins in the glomerular capillary loop which may contribute to defects in ultrafiltration, many of the disease mechanisms of nephrotic syndrome remain unresolved. In this study, we show that the glomerular expression of angiopoietin-like-4 (Angptl4), a secreted glycoprotein, is glucocorticoid sensitive and is highly upregulated in the serum and in podocytes in experimental models of MCD and in the human disease. Podocyte-specific transgenic overexpression of Angptl4 (NPHS2-Angptl4) in rats induced nephrotic-range, and selective, proteinuria (over 500-fold increase in albuminuria), loss of glomerular basement membrane (GBM) charge and foot process effacement, whereas transgenic expression specifically in the adipose tissue (aP2-Angptl4) resulted in increased circulating Angptl4, but no proteinuria. Angptl4 −/− mice that were injected with lipopolysaccharide (LPS) or nephritogenic antisera developed markedly less proteinuria than did control mice. Angptl4 secreted from podocytes in some forms of nephrotic syndrome lacks normal sialylation. When we fed the sialic acid precursor N-acetyl-D-mannosamine (ManNAc) to NPHS2-Angptl4 transgenic rats it increased the sialylation of Angptl4 and decreased albuminuria by more than 40%. These results suggest that podocyte-secreted Angptl4 has a key role in nephrotic syndrome.
As part of our studies to identify mechanisms of proteinuria, we injected rats with the γ2 fraction of nephrotoxic serum (γ2-NTS), an antiserum that is reactive to many podocyte proteins and induces complement-and leukocyte-independent glomerular injury by direct antibody binding 2 . We assembled a panel of differentially expressed glomerular genes 3 and investigated in detail two genes for their involvement in the pathogenesis of proteinuria. One of these genes encodes the transcriptional factor zinc fingers and homeoboxes 3 (Zhx3), which is expressed in podocytes and has a major role in the pathogenesis of primary glomerular disease 3 . The other gene, Angptl4, was highly upregulated in podocytes, and is the focus of investigation in this paper.
Angiopoietin-like proteins have been implicated in the development of hypertriglyceridemia 4 and tumor metastasis 5 and have some functional properties that are different from the angiopoietins. Angptl4 is highly expressed in the liver and adipose tissue and is strongly induced by fasting in these organs 6 . It is a target gene of the nuclear receptors peroxisome proliferator and activator of transcription-α (Ppar-α) 6 and Ppar-γ 7 and is an apoptosis survival factor for vascular endothelial cells under normoxic conditions 8 . Angptl4 is a potent inhibitor of lipoprotein lipase 4 and induces marked hypertriglyceridemia after intravenous injection or adenovirusmediated expression 9, 10 . Other studies have shown that its expression is lower in cardiomyocytes and skeletal muscle, and northern blot analysis has shown low expression in whole kidney 7 . Population-based studies of ANGPTL4 have identified variants that affect triglyceride levels in humans 11, 12 . Most normal circulating Angptl4 in rodents is secreted from the liver as a cleaved protein that binds high-density lipoprotein particles 13 . To our knowledge, it has not previously been shown that Angptl4 has a role in proteinuria.
Angptl4 mRNA was strongly upregulated (70.45 ± 4.14 fold increase; mean ± s.e.m.) in rat glomeruli at the peak of complement-and leukocyte-independent heterologous-phase proteinuria 3 24 h after injection of γ2-NTS (Fig. 1a,b and Supplementary Fig. 1 ). Injection of LPS ( Fig. 1c ) and γ2-NTS ( Supplementary Fig. 2a,b ) induced significantly less proteinuria ( Fig. 1c and Supplementary Fig. 2a ) and foot process effacement ( Supplementary Fig. 2b ) in Angptl4 −/− than in Angptl4 +/+ mice. Normal rat glomeruli express Angptl4 in a capillary loop pattern that localizes with podocyte protein CD2 adaptor protein (CD2AP; Fig. 1d ). We noted early (day 3, before the onset of proteinuria) and progressive upregulation of Angptl4 mRNA expression in young rats after intravenous injection of a single dose of puromycin aminonucleoside (the puromycin aminonucleoside nephrosis, or PAN, model shows a peak of up to 80-fold increase in glomerular Angptl4 mRNA expression Podocyte-secreted angiopoietin-like-4 mediates proteinuria in glucocorticoid-sensitive nephrotic syndrome Fig. 2c ).
In passive Heymann nephritis, we saw a smaller increase in Angptl4 expression, starting after the onset of proteinuria ( Fig. 1e) . Angptl4 mRNA expression did not change in anti-Thy1.1 nephritis (induced by injecting rats with Thy1.1-specific antibody) or in collapsing FSGS 14 (Fig. 1e) . Angptl4 expression increased markedly in podocytes ( Fig. 1f ) after the induction of PAN, with substantial additional overlap with the GBM, and this was confirmed by immunogold electron microscopy ( Fig. 1g) . We also noted reduced expression of GBM heparan sulfate proteoglycans in glomeruli in the PAN model ( Fig. 1f) .
To study the biological role of Angptl4 upregulation in nephrotic syndrome, we assessed Angptl4 expression in podocytes in a previously established Angptl4 transgenic mouse model 13 ( Fig. 2a-d and Supplementary Fig. 2d,e ). Glomeruli appeared normal by light microscopy (Fig. 2a) . We noted increased glomerular expression of Angptl4, but not of another podocyte-expressed protein, zona occludens 1 (ZO-1; Fig. 2a ) in 3-month-old transgenic mice. Expression of Angptl4 colocalized with podocyte-expressed CD2AP (Supplementary Fig. 2d ). Electron microscopy revealed 50% effacement or broadening of foot processes (Fig. 2b) . Immunogold electron microscopy showed a large number of gold particles in podocyte foot processes, GBM and close to the endothelial cell surface ( Fig. 2c) , especially in areas opposite to foot process effacement ( Fig. 2c, right) . These mice had mild proteinuria ( Fig. 2d) .
Given that Angptl4 upregulation and proteinuria in Angptl4 transgenic mice are lower than those observed in PAN and human MCD, we developed additional transgenic models. We generated transgenic rats, as most models of primary glomerular disease have been developed in this species. To independently study the effects of increased podocyte expressed and circulating Angptl4, both of which are noted in human MCD, on glomerular function, we developed podocytespecific (NPHS2-Angptl4, increased podocyte expression) and adipose tissue-specific (aP2-Angptl4, increased circulating Angptl4 secreted from adipose tissue) transgenic rats ( Fig. 2e) . Analysis of mRNA expression in organs that normally express Angptl4 confirmed the specificity of expression ( Fig. 2f and Supplementary Fig. 2f ). In keeping with the normal expression pattern of the NPHS2 promoter, we noted significant expression in the pancreas. Histological assessment of 3-month-old heterozygous male NPHS2-Angptl4 transgenic rats showed normal-appearing glomeruli with prominent podocytes on light microscopy ( Fig. 2g ) and increased glomerular expression of Angptl4 by confocal imaging (Fig. 2h ) that overlapped with podocytelocalized nephrin and GBM-localized heparan sulfate proteoglycans. The glomerular protein expression in the NPHS2-Angptl4 transgenic rats ( Fig. 2h) is comparable with expression noted in PAN rats ( Fig. 1f) .
Electron microscopy of 5-month-old homozygous transgenic rats showed diffuse foot process effacement ( Fig. 2i and Supplementary  Fig. 3a ). Using immunogold electron microscopy in homozygous NPHS2-Angptl4 transgenic rats, we found a correlation between gold particle clustering in the GBM and the development of foot process effacement, which is first noted at around 3 months ( Fig. 2j) . In situ hybridization for Angptl4 ( Supplementary Fig. 3b ) showed a selective increase in the signal in glomeruli in a peripheral podocyte distribution. In contrast to the NPHS2-Angptl4 transgenic rats, the aP2-Angptl4 transgenic rats had morphologically normal glomeruli by light microscopy (Fig. 2g ) and electron microscopy (data not shown).
There was marked albuminuria in both NPHS2-Angptl4 transgenic rat founder lines. Female homozygous and male heterozygous rats developed albuminuria at 1 month ( Fig. 3a-c and Supplementary  Fig. 3c ). The increase in albuminuria was up to 100-fold in homozygous females, up to 20-fold in heterozygous males and more than 500-fold in homozygous males over time. Heterozygous females were not albuminuric. More than 90% of urinary protein comprised intact albumin ( Fig. 3d and Supplementary Fig. 3d ), which means that these rats are, to our knowledge, the first model of selective proteinuria, a key feature of human MCD. Blood pressure was significantly lower in proteinuric heterozygous NPHS2-Angptl4 transgenic rats than in wild-type controls (Supplementary Fig. 3e ). By contrast, aP2-Angptl4 transgenic rats did not develop albuminuria (Fig. 3d) even though they are marked by high circulating Angptl4 concentrations ( Supplementary Fig. 4a-d) . Despite upregulation of Angptl4 in the pancreas in NPHS2-Angptl4 transgenic rats, circulating Angptl4 was not elevated but rather was marginally reduced ( Supplementary  Fig. 4a-d) , owing to the presence of proteinuria. In keeping with the proteinuric effects of podocyte-secreted Angptl4, NPHS2-Angptl4 transgenic rats developed more proteinuria (Fig. 3e ) than wild-type littermates after induction of PAN. The levels of serum electrolytes, creatinine and glucose in transgenic rats were indistinguishable from those of wild-type rats.
As previously reported 15 , proteinuria in the PAN model was partially glucocorticoid sensitive on day 6 ( Fig. 3f) . Studies of the expression of Angptl4 mRNA showed a significant reduction in Angptl4 expression in glucocorticoid-treated rats on day 6 ( Fig. 3g) , which suggested that Angptl4 was glucocorticoid sensitive in vivo. The early increase in Angptl4 mRNA that we saw on day 3 after induction of PAN (before the onset of proteinuria) was also reversed by glucocorticoid treatment. In addition, we detected Angptl4 oligomers in the urine in experimental models of proteinuria ( Supplementary Fig. 4e,f) .
We investigated the loss of GBM charge in transgenic rats and mice (Supplementary Fig. 5 ). Alcian blue and polyethyleneimine staining showed that NPHS2-Angptl4 transgenic rats had marked loss of GBM charge (Supplementary Fig. 5a,b,d) . As also seen in PAN rats (Fig. 1f) , GBM-localized heparan sulfate proteoglycan abundance was reduced in NPHS2-Angptl4 transgenic rats (Supplementary Fig. 5c ).
Immunoblotting of glomerular proteins typically underestimates Angptl4 production, as the protein is rapidly secreted. On twodimensional gel electrophoresis, most Angptl4 in normal glomeruli migrated as glycosylated low-order oligomers at neutral pI (Fig. 4a) , although we also saw less prominent spots for both glycosylated intact 70-kDa and cleaved or nonglycosylated 45-kDa monomeric forms ( Supplementary Fig. 6a,b) . The 45-kDa protein, but not the oligomers, was threonine phosphorylated (Supplementary Fig. 6a) . In the PAN model, expression of both the neutral-pI oligomers, which were reactive with sialic acid-binding lectin from Maackia amurensis (MAA), and the high-pI oligomers, which did not react with MAA, were increased (Fig. 4a,b) . This increase was blunted by glucocorticoids, although there were still disproportionately higher amounts of high-pI oligomers (Fig. 4a,b) .
Next, we studied the sialylation of Angptl4 in vitro (Fig. 4c,d and Supplementary Fig. 6c,d) with Angptl4-HEK293 ( Supplementary   Fig. 7a-c) and Angptl4-glomerular epithelial cell (GEC) stable cell lines ( Supplementary Fig. 7d,e ). Incubation of both stable cell lines with the sialic acid precursor ManNAc resulted in a shift of the secreted Angptl4 protein toward neutral pI, with increased reactivity to MAA, which suggested that sialylation had a key role in the differential electrophoretic migration of Angptl4 (Fig. 4c,d) .
As we saw an increase in hyposialylated Angptl4 in the PAN model, we investigated whether this lack of sialylation was involved in the pathogenesis of proteinuria. More than half of glomerular Angptl4 in NPHS2-Angptl4 transgenic rats was hyposialylated and migrated at a high pI (Fig. 4e,f and Supplementary Fig. 6e ). NPHS2-Angptl4 transgenic rats that received ManNAc in tap water had a 40.6 ± 3.3% (mean ± s.e.m.) reduction in albuminuria over a 12-d period compared to baseline ( Fig. 4g and Supplementary Fig. 8a,b) , and this albuminuria returned to levels comparable to those in control untreated transgenic rats after 24 d of washout. Densitometry analysis of western blots for glomerular Angptl4 from rats killed after 12 d of ManNAc treatment (Fig. 4f) showed an increase in the neutral-pI Angptl4 fraction from 43.3 ± 4.2% (mean ± s.e.m.) in control rats to 72.9 ± 1.4% in ManNAc-treated rats. The neutral pI fraction was also reactive with sialic acid-binding lectin from Sambucus nigra (SNA I; Fig. 4e ), confirming the increase in sialylation of Angptl4 in ManNAc-treated rats. We did not note any changes in the quantitative expression of podocalyxin, another sialylated glomerular glycoprotein that is crucial for the structural integrity of podocytes. Two-dimensional gel electrophoresis did not reveal any significant shift in the migration of podocalyxin toward a lower pI (below 7) in ManNAc-treated transgenic rats (Supplementary Fig. 6f-h) .
In normal rodents, most of the circulating Angptl4 is secreted by the liver and is bound to high-density lipoprotein 13 . In transgenic rats, most glomerular Angptl4 was either monomeric or formed low-order oligomers, whereas circulating Angptl4 formed mostly middle-order and high-order oligomers (Supplementary Fig. 8c ). This may be one reason why the circulating form does not enter the GBM in aP2-Angptl4 transgenic rats. Most circulating Angptl4 in these rats migrates between pI 5 and pI 7 (Supplementary Fig. 4a,b) and is therefore unlikely to bind avidly to anionic GBM proteins in a charge-dependent manner.
Of the various forms of primary glomerular disease examined, the PAN model showed the greatest upregulation of Angptl4 expression. Expression was upregulated less prominently and later in the disease course in passive Heymann nephritis and was unchanged Supplementary  Fig. 3d ). MW, molecular weight; NA, not applicable. (e) Proteinuria after induction of low-dose PAN in heterozygous in non-HIV collapsing FSGS. Therefore, we used confocal imaging to study Angptl4 expression in biopsies from individuals with MCD (n = 5) ( Supplementary Fig. 9) . We found increased expression in a podocyte distribution with additional GBM overlap in all five biopsies, compared with healthy controls. In addition, we found Angptl4 oligomers in the urine of four more individuals with MCD ( Supplementary Fig. 10a,b and Supplementary Table 1) , and the plasma of these subjects contained distinctive patterns of circulating Angptl4 (Supplementary Fig. 10c-e ).
The effects of podocyte-secreted Angptl4 on the glomerular capillary loop in nephrotic syndrome are illustrated in Supplementary  Figure 11 . Transgenic expression of Angptl4 from podocytes reproduced some of the key features of human MCD, including the characteristic morphological changes, nephrotic-range, selective proteinuria and loss of GBM charge. One feature that was missing was the sudden onset of proteinuria. It is possible that this feature is contributed to by other genes or proteins that are concomitantly dysregulated with Angptl4 in human MCD, and that these proteins may accelerate the interaction or transport of Angptl4 across the glomerular capillary loop. These results show that Angptl4 might be involved in the pathogenesis of MCD in humans. The development of albuminuria in NPHS2-Angptl4 transgenic rats at 1 month, when podocyte foot processes were intact and the GBM contained scattered immunogold particles, suggests that podocyte-secreted Angptl4 induced a filtration defect in the GBM. Clustering of immunogold particles in the GBM coincided with the development of foot process effacement and a sharp increase in proteinuria at around 3 months, suggesting that there was a complex interaction between Angptl4, GBM proteins and the podocyte-GBM interface.
The fact that Angptl4 is sensitive to glucocorticoids in the PAN model supports the idea that this gene is involved in glucocorticoid-sensitive nephrotic syndrome. Other podocyte-expressed, glucocorticoid-sensitive genes have been described 15 . Mutations in one of these genes, NPHS2, most often result in the development of glucocorticoid-resistant FSGS 16 . Of proteins secreted by podocytes, there is evidence that vascular endothelial growth factor-α is involved in human thrombotic microangiopathy 17 , whereas experimental overexpression of Angpt2 in mice results in a 2-2.5-fold increase in albuminuria 18 . Neither of these is known to be directly involved in the pathogenesis of glucocorticoid-sensitive nephrotic syndrome.
The absence of proteinuria in aP2-Angptl4 transgenic rats, despite high circulating Angptl4, highlights the role of localized production of Angptl4 by podocytes in proteinuric disease. Also, the commonly observed 60-to 80-fold peak upregulation of glomerular Angptl4 expression in the PAN model is close to the 120-fold increase found in proteinuric heterozygous male NPHS2-Angptl4 transgenic rats, thereby making these rats a suitable model for future studies on nephrotic syndrome.
The secretion of high-pI Angptl4 by podocytes in PAN is likely to facilitate the tethering of Angptl4 to the GBM, and Angptl4 has been shown to bind heparan sulfate proteoglycans 19 . This finding correlates well with the finding of reduced GBM charge in rodents with transgenic expression of Angptl4 from podocytes. Our studies do not provide strong evidence that GBM charge is related to proteinuria, as, despite mild proteinuria in the transgenic mouse model, the reduction in GBM charge is similar between the Angptl4 transgenic mouse and NPHS2-Angptl4 transgenic rat models. It is likely that charge facilitates the transit of high-pI Angptl4 across the GBM against the direction of fluid flow. Figure 4 Relationship between Angptl4 sialylation and proteinuria. (a) Two-dimensional gel electrophoresis and western blot of protein from perfused glomeruli show neutral and high pI, low-order Angptl4 oligomers (pink and orange arrows) in control, PAN day 6 and glucocorticoid-treated PAN day 6 rats (from experiment in Fig. 3f ). Reactivity of sialic acid binding lectin MAA to these oligomers is also assessed (exemplified for PAN, excerpts from independent blots). (b) Densitometry of total, neutral-and high-pI oligomers shown in a. Anti-Angptl4
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Changes in sialylation might explain some of the variations in pI, as increasing the sialylation of Angptl4 in vitro induces migration from high toward neutral pI. There are at least two potential O-glycosylation and two N-glycosylation sites in rat and human Angptl4 where sialic acid residues could be incorporated. The reduction in albuminuria in NPHS2-Angptl4 transgenic rats fed with ManNAc, and the increase in the sialylation of glomerular Angptl4 in these rats, suggest that hyposialylation might be one mechanism by which Angptl4 overexpression contributes to proteinuria. Therefore, treatment with sialic acid precursors constitutes a potential therapeutic tool to reduce proteinuria in some forms of nephrotic syndrome. ManNAc therapy has been used to improve muscle weakness 20 and the severe glomerular phenotype 21 seen in mice with mutations in the GNE gene, which is mutated in people with hereditary inclusion body myopathy. However, these individuals do not show a kidney phenotype.
The demonstration that Angptl4 is involved in proteinuria is likely to stimulate studies of its role in other aspects of nephrotic syndrome. Glucocorticoids have been reported to increase Angptl4 expression in adipose tissue, and could potentially increase levels in the circulation 22 . Circulating Angptl4 increases plasma triglycerides by inhibiting tissue uptake through inactivation of endothelial bound lipoprotein lipase activity in target organs 4 . Future studies will address whether some of the hypertriglyceridemia in nephrotic syndrome is contributed to by Angptl4 leaking from glomeruli into the circulation. It will be equally necessary to study the interactions between Angptl4 and specific GBM proteins and to identify DNA motifs in the Angptl4 gene that mediate glucocorticoid sensitivity.
MeTHoDS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/.
Note: Supplementary information is available on the Nature Medicine website.
ACKnoWLEdgMEntS
We thank B. Spiegelman (Dana-Farber Cancer Institute) for the mouse aP2 promoter construct; L. Holzman (University of Michigan) for the human NPHS2 promoter construct; P. Mundel (University of Miami) for mouse GECs; T. van Kuppevelt (Radboud University Nijmegen Medical Center) for the heparan sulfate proteoglycan-specific antibody p1113; D. Salant (Boston University) for γ2-NTS; and A. Köster (Eli Lilly) for Angptl4 −/− mice. We also thank G. Bai for the generation of probe for in situ hybridization; S. Shastry for some ELISA assays for rat and mouse albumin; S. Rahmanuddin for selected immunogold studies and polyethyleneimine studies; F. Mattijssen for mouse LPS study; J. Novak for advice on choice of lectins; and Y.S. Kanwar and M. Venkatachalam for useful discussions on heparan sulfate proteoglycans. Supported by the US National Institutes of Health (R56DK077073, R01DK077073 to S.S.C.), Norman S. Coplon Satellite Research Grant to S.S.C. and CONACYT 111 grant to C.A.-C. We thank the University of Alabama at Birmingham-University of California-San Diego George O'Brien Center Core C for measuring mouse urine creatinine by mass spectrometry. The use of sialic acid precursors, including ManNAc, to treat proteinuria and nephrotic syndrome is covered by US Provisional Application 61/351,865 filed by S.S.C.
AUtHoR ContRIBUtIonS
L.C.C. was lead postdoctoral fellow, conducted most of the animal studies, generated stable cell lines and purified recombinant protein, maintained transgenic rats and conducted all studies on transgenic rats, confocal imaging and in situ hybridization, most gene expression studies and selected two-dimensional gel studies. C.A.-C. interpreted and analyzed light microscopy, electron microscopy and immunogold electron microscopy sections for the study and conducted studies on induction of collapsing glomerulopathy in rats. C.M. conducted most of the two-dimensional gel electrophoresis and proteomic work, and most of the albumin ELISA assays. E.S. acted as electron microscopist and morphometrics expert, prepared tissue for electron microscopy, conducted and imaged conventional and most immunogold electron microscopy studies, and conducted alcian blue charge studies. W.W.B. provided human sera and assisted in study design and preparation of the manuscript. S.K. conducted studies on Angptl4 transgenic mice, provided tissue for histological and gene expression analysis, conducted Angptl4 −/− mouse studies with NTS and made substantial contributions to the preparation of the manuscript. S.S.C. acted as senior investigator, planned and supervised the study, generated constructs for transgenic rats, conducted molecular biology and gene expression studies, conducted early animal studies, and wrote and revised the manuscript with input from the other authors.
